Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a p...

Read More

PHAT Performance At-A-Glance

RISK EFFICIENCY

0.72

Phathom Pharmaceuticals, Inc.'s risk efficiency is 0.72, which is OK. By comparison, the S&P500 is 0.44.

Increasing quickly  over the past 4 weeks.

DSCORE

7.55%

Phathom Pharmaceuticals, Inc.'s dScore is 7.55% , which is more volatile than the S&P500 (1.74%).

GROWTH

58.22%

Phathom Pharmaceuticals, Inc. has grown by 58.22% over the past year.  By comparison, the S&P500 has lost NaN%.

Increasing slightly over the past 4 weeks.